^
    7ms
    A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=762, Not yet recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
    New P1 trial
    |
    cisplatin • carboplatin • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium • AiRuiLi (adebrelimab) • GSK5764227 • HS-10370 • PM1080
    1year
    A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=350, Not yet recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
    New P1 trial • Metastases
    |
    cisplatin • carboplatin • pemetrexed • AiRuiLi (adebrelimab) • HS-10370
    over2years
    Phase 1/2 Study of HS-10370 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=176, Recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    HS-10370
    over3years
    Phase 1/2 Study of HS-10370 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=176, Not yet recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    HS-10370